# Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy

> **NCT03355560** · PHASE2 · COMPLETED · sponsor: **Trisha Wise-Draper** · enrollment: 39 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03355560
- **Lead sponsor:** Trisha Wise-Draper
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-06
- **Primary completion:** 2024-01-01
- **Final completion:** 2026-04-15
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03355560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03355560, "Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03355560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*